Skip to main content
VTGN
NASDAQ Life Sciences

Two Directors Not Seeking Re-election Amidst Financial Challenges

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.668
Mkt Cap
$28.312M
52W Low
$0.43
52W High
$5.14
52W Position info
55% above low
Off High info
87% below high
Rel. Volume info
2.4× avg
Market data snapshot near publication time

VTGN sits 55% above its 52-week low of $0.43 on elevated volume (2.4× avg).

Summary

Two Vistagen Therapeutics board directors have announced they will not seek re-election, signaling potential concerns amidst the company's ongoing financial difficulties.


Key Events · Executive and Board Changes · VTGN

  • Two Directors Not Seeking Re-election

    Ms. Margaret FitzPatrick and Dr. Joanne Curley, both members of the Board of Directors, notified the company of their decision not to stand for re-election at the 2026 Annual Meeting of Stockholders. They will continue to serve until the end of their terms.

  • Context of Financial Distress

    This announcement follows the company's recent 10-K filing on June 15, 2026, which disclosed severe financial challenges, substantial doubt about its ability to continue as a going concern, and a Nasdaq delisting threat.


Analysis · VTGN · Life Sciences

The decision by two board directors not to seek re-election adds to concerns about Vistagen Therapeutics' stability, especially following the recent 10-K filing which highlighted severe financial challenges and going concern doubts. This suggests a potential lack of confidence in the company's future leadership or strategic direction.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, VTGN was trading at $0.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.3M. The 52-week trading range was $0.43 to $5.14. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VTGN - Latest Insights

VTGN
Nov 13, 2026, 4:11 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.1805
Real-time Price: $0.1615 info
Change: -$0.019 (-11%) info
Market Cap: $7.556M info
VTGN
Nov 13, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.1805
Real-time Price: $0.1615 info
Change: -$0.019 (-11%) info
Market Cap: $7.556M info
VTGN
Nov 09, 2026, 8:34 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.172
Real-time Price: $0.1615 info
Change: -$0.0105 (-6%) info
Market Cap: $7.556M info
VTGN
Oct 30, 2026, 5:24 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.1714
Real-time Price: $0.1615 info
Change: -$0.0099 (-6%) info
Market Cap: $7.556M info
VTGN
Oct 09, 2026, 5:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.2461
Real-time Price: $0.1615 info
Change: -$0.0846 (-34%) info
Market Cap: $7.556M info